Somatostatin analogues and the mammalian target of rapamycin (mTOR) inhibitor, everolimus, prolong progression-free survival (PFS) in patients with inoperable, advanced (metastatic) gastroenteropancreatic NET (GEP-NET), and sunitinib is approved for the treatment of advanced (metastatic) pancreatic NET [2–5]. Here, MTOR is linked to pancreatic neuroendocrine tumor.